All News

Updates to the 8th edition of AJCC's staging manual include incorporation of more nonanatomic features. Oncology Clinical Specialist Chelsea Backler discussed key changes during the 2018 ONS Congress.

Cancer patients get inundated with advice, but how much of it can be trusted? Patient advocate Suzie Siegel weighs in.

A study led by Dr. Jun Mao of MSKCC found CBT and acupuncture each yielded clinically meaningful and durable sleep-related QOL improvements.

Detailed education and other initiatives related to CHG cloth use boosted bathing compliance rates by 95% in 14 months, and decreased CLABSI by 8%.

After non-oncology units received comprehensive safety kits for handling oral hazardous drugs, chemo handling precautions at Maine Medical Center increased significantly.

Recurrence risk was greater in sarcopenic patients, and greater alpha-fetoprotein and microvascular invasion were independent risk factors.

A retrospective study of ICIs by French investigators found manageable toxicity in patients over age 70, and survival outcomes comparable to younger patients.

A Cleveland Clinic team found patients with false-positive results subsequently become more involved in cancer screening programs.

A doctor sits down with Cancer to gauge its feelings towards new immunotherapy agents, lower smoking rates, and the US obesity epidemic.

In the US, cancer treatment is more expensive for patients younger than 65, according to a Kaiser Permanente study.

Patients with alcohol-related HCC had worse OS than other HCC patients, mainly due to poorer liver function and more unfavorable tumor characteristics at diagnosis.

In this podcast, Dr. Debra Patt discusses trends in cancer care, including how treatments are becoming more personalized and less toxic.

Stage III colon cancer patients adhering to ACS Nutrition and Physical Activity Guidelines for Cancer Survivors after diagnosis had a 42% lower risk of death.

A large prospective analysis of data from the UK Women’s Cohort Study found an association between red meat consumption and distal colon disease risk.

A USCF team has uncovered molecular insights into meningioma biology that could lead to new, less toxic treatment approaches.

A new joint review from ASCO and CAP found insufficient evidence of clinical validity and utility for the use of most ctDNA assays in advanced cancer.

An analysis presented at SGO 2018 concluded strong and consistent clinician recommendations might boost HPV vaccination rates among teens, particularly boys.

The NCCN has released new clinical practice guidelines for the management of cancer in people living with HIV.

The FDA has granted Breakthrough Therapy and Fast Track designation to GC4419, for reduction of severe oral mucositis caused by radiation therapy.

In this UK observational study, being obese was linked with an increased risk for colorectal cancer but undergoing prior obesity surgery was not.

In this interview, Dr. Stephanie Blank discusses the recently released updates to the US Preventive Services Task Force Guideline on Ovarian Cancer Screening, and how patients and clinicians should interpret them and take action.

In a Canadian survey, lung cancer patients were more likely to report that they should be asked about their smoking status at every clinic visit.

Researchers examined more than 750 pedigrees of familial hematologic malignancies and found that the same genetic alteration may be responsible for Langerhans cell histiocytosis, acute myeloid leukemia, and primary idiopathic myelofibrosis.

Patients who received Bacteroides-targeting antibiotics had a median PFS of 18 months compared with 8 months in patients with no antibiotic use.

In a study of over 100,000 adults, overall cancer risk, particularly of breast cancer, was associated with dietary intake of ultra-processed foods.

Earlier collection of patient-reported outcomes could potentially improve comprehensive cancer care.

A review of the rules of the road for doctors, because everyone remembers their first license.

The significant tumor shrinkage and immunologic changes observed support a complementary role of SBRT and PD-1 immunotherapy, investigators concluded.

Early-phase data on larotrectinib validate TRK fusions as therapeutic targets and show they lead to tumor-agnostic sensitivity to this agent.

An early phase trial found that it is feasible to combine nivolumab immunotherapy with radiation therapy and chemotherapy in patients with newly diagnosed local-regionally advanced head and neck cancers.